WO2013108800A1 - 置換フェニルアゾール誘導体 - Google Patents
置換フェニルアゾール誘導体 Download PDFInfo
- Publication number
- WO2013108800A1 WO2013108800A1 PCT/JP2013/050710 JP2013050710W WO2013108800A1 WO 2013108800 A1 WO2013108800 A1 WO 2013108800A1 JP 2013050710 W JP2013050710 W JP 2013050710W WO 2013108800 A1 WO2013108800 A1 WO 2013108800A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- added
- mixture
- solution
- reference example
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a novel substituted phenylazole derivative having a hypoglycemic action and / or a ⁇ -cell or pancreas protecting action or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing these as an active ingredient.
- Diabetes is a metabolic disease mainly characterized by chronic hyperglycemia due to insufficient insulin action.
- drug therapy is generally administered together with diet therapy and exercise therapy.
- Oral hypoglycemic agents that are a type of anti-diabetic agent include biguanides or thiazolidinediones that improve insulin resistance, sulfonylureas or glinides that promote insulin secretion from pancreatic ⁇ cells, and ⁇ that inhibit sugar absorption -Glucosidase inhibitors are used.
- the present invention is a compound having a new structure not described or suggested in the above patent document and having an excellent hypoglycemic effect or ⁇ -cell or pancreatic protective action, or a pharmaceutically acceptable salt thereof, Provided are a pharmaceutical composition having an excellent therapeutic effect and / or preventive effect on type 1 diabetes, type 2 diabetes and the like that cause an increase in blood sugar due to abnormal glucose metabolism, and a pharmaceutical composition having a ⁇ -cell or pancreatic protective action For the purpose.
- R 5 is —H, or a C1-C6 alkyl group, a C3-C6 cycloalkyl group optionally substituted with 1 to 3 —OH, or
- R 2 is -F; and
- R 4 is
- R 1 is —C ( ⁇ O) —NH—R 5
- R 2 is —F
- R 4 is
- R 5 is a hydroxyisopropyl group or a cyclopropyl group, or a pharmaceutically acceptable salt thereof;
- R 5 is a C1-C6 alkyl group optionally substituted with 1 to 3 —OH, or a pharmaceutically acceptable salt thereof; (5) Ring A is
- R 2 is -F; and
- R 3 is -CH 3 , R 4
- R 5 is —H, or a C1-C6 alkyl group or a C3-C6 cycloalkyl group optionally substituted with 1 to 3 —OH, or the compound according to (1), A pharmaceutically acceptable salt thereof; (6) Ring A is
- R 2 is -F; and
- R 4 is
- R 5 is —H, or a C1-C6 alkyl group or a C3-C6 cycloalkyl group optionally substituted with 1 to 3 —OH, or the compound according to (1), A pharmaceutically acceptable salt thereof; (7) General formula (II):
- R 3 is —CH 3 or —C 2 H 5
- R 6 is a C1-C6 alkyl group or C3-C6 cycloalkyl group optionally substituted with 1 to 3 —OH.
- substituent group ⁇ is —OH, —OC ( ⁇ O) —O—CH 3 or —OC ( ⁇ O) —NH—C 2 H 5 ), or a pharmaceutically acceptable compound thereof Salts that can be made; (9) Below: 1- [4- (4- ⁇ 1- [4- (cyclopropylcarbonyl) phenoxy] propyl ⁇ -2H-1,2,3-triazol-2-yl) -2-fluorophenyl] -3- (2- Hydroxyethyl) urea; 4- ⁇ 4-[(1R) -1- ⁇ [6- (cyclopropylcarbonyl) pyridin-3-yl] oxy ⁇ ethyl] -2H-1,2,3-triazol-2-yl ⁇ -N- [ (1R, 2R) -2,3-dihydroxy-1-methylpropyl] -2-fluorobenzamide; 1- (4- ⁇ 4-[(1R) -1- ⁇ [6- (cyclopropyl
- R 3 is —CH 3 or —C 2 H 5
- R 6 is a C1-C6 alkyl group or C3-C6 cycloalkyl optionally substituted with 1 to 3 —OH.
- R 7 is a group
- X is CH or N
- R 3 is —CH 3 or —C 2 H 5
- R 8 is —H or 1 to 3 selected from the substituent group ⁇ .
- a substituted which may be substituted C1 ⁇ have C6 alkyl group with a group
- R 9 is
- substituent group ⁇ is —OH, —OC ( ⁇ O) —O—CH 3 or —OC ( ⁇ O) —NH—C 2 H 5 ) or a pharmaceutically acceptable salt thereof It is an acceptable salt.
- X, R 1 and R 3 are as defined above, or a pharmaceutically acceptable salt thereof.
- X, R 3 and R 5 are as defined above, or a pharmaceutically acceptable salt thereof.
- One embodiment of the present invention is a compound represented by the general formula (VI):
- X, R 1 and R 3 are as defined above, or a pharmaceutically acceptable salt thereof.
- X, R 1 , R 3 and R 4 are as defined above, or a pharmaceutically acceptable salt thereof.
- C1-C6 alkyl group means a linear or branched alkyl group having 1 to 6 carbon atoms. Specific examples include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group and the like.
- C3 to C6 cycloalkyl group means a saturated cyclic hydrocarbon group having 3 to 6 carbon atoms, and examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group.
- the “pharmaceutically acceptable salt” refers to a salt formed by reacting the compound of the present invention with an acid or a base.
- Salts include hydrohalides such as hydrofluoride, hydrochloride, hydrobromide and hydroiodide; inorganic acid salts such as nitrate, perchlorate, sulfate and phosphate Methanesulfonate, trifluoromethanesulfonate, lower alkanesulfonates such as ethanesulfonate; arylsulfonates such as benzenesulfonate, p-toluenesulfonate; acetate, malate, fumarate Acid salts, succinates, citrates, ascorbates, tartrate, oxalates, maleates, and other organic acid salts; sodium, potassium, lithium, and other alkali metal salts; calcium salts, magnesium salts Alkaline earth metal salts such as; metal salts such as aluminum salts and iron salts; inorganic salts such as ammonium salts; t-octylamine salts, dibenzylamine salt
- the compound of the present invention may absorb water and become a hydrate when left in the air, for example, and such a hydrate is also included in the salt of the present invention.
- the present invention includes all optical isomers of the compounds represented by the general formulas (I) to (VIII) and mixtures in arbitrary proportions of the optical isomers.
- Such optical isomers can also be produced, for example, using raw materials having optical activity instead of the raw materials shown in the reference examples or examples described later.
- compounds prepared by referring to Reference Examples and Examples to be described later are used in optical resolution methods known in the art, for example, diastereomeric methods, enzymatic reaction methods, optical resolution methods such as chromatography, etc. It can also be obtained.
- the present invention can also include compounds in which one or more of the atoms of the compounds represented by the general formulas (I) to (VIII) are substituted with isotopes of the atoms.
- isotopes There are two types of isotopes: radioactive isotopes and stable isotopes.
- isotopes include hydrogen isotopes ( 2 H and 3 H), carbon isotopes ( 11 C, 13 C and 14 C), nitrogen isotopes ( 13 N and 15 N), oxygen isotopes ( 15 O, 17 O and 18 O), fluorine isotopes ( 18 F) and the like.
- a composition containing a compound labeled with an isotope is useful, for example, as a therapeutic agent, prophylactic agent, research reagent, assay reagent, diagnostic agent, in vivo diagnostic imaging agent, and the like. All isotope-labeled compounds and mixtures of isotope-labeled compounds in any proportion are also encompassed by the invention.
- An isotope-labeled compound can be produced by a method known in the art, for example, by using a raw material labeled with an isotope instead of the raw material in the production method of the present invention described later.
- the present invention can also include prodrugs of the compounds represented by the general formulas (I) to (VIII).
- a prodrug is a derivative of a compound represented by the general formulas (I) to (VIII) and refers to a compound that is enzymatically or chemically converted into the compound of the present invention in vivo.
- Prodrugs include compounds in which the amino group in the molecule is acylated, alkylated or phosphorylated, compounds in which the hydroxy group in the molecule is acylated, alkylated or phosphorylated (for example, PovlP Krogsgaard- Larsen et al., “A Textbook of Drug Design and Development, 2nd edition, harwood academic publishers, 1996, pp. 351-385).
- Such prodrugs can be produced from the compounds represented by the general formulas (I) to (VIII) by methods known in the art.
- the compound of the present invention can be easily produced from a known compound according to Reference Examples and Examples described later.
- the compound of the present invention or a pharmaceutically acceptable salt thereof has an excellent hypoglycemic action, type 1 diabetes, type 2 diabetes, gestational diabetes, hyperglycemia due to other factors, impaired glucose tolerance (impaired glucose tolerance) : IGT), obesity, diabetes-related diseases (eg, hyperlipidemia, hypercholesterolemia, dyslipidemia, hypertension, fatty liver, metabolic syndrome, edema, heart failure, angina, myocardial infarction, arteriosclerosis, Efficacy of pharmaceutical compositions that can be used for the treatment and / or prevention of hyperuricemia, gout, etc.) or diabetic complications (eg retinopathy, nephropathy, neuropathy, cataract, foot gangrene, infection, ketosis, etc.) Can be used as an ingredient.
- diabetes-related diseases eg, hyperlipidemia, hypercholesterolemia, dyslipidemia, hypertension, fatty liver, metabolic syndrome, edema, heart failure, angina, myocardial infarction, arteriosclerosis
- the compound of the present invention or a pharmaceutically acceptable salt thereof has excellent ⁇ -cell or pancreas protective action, it can be used as an active ingredient of a pharmaceutical composition that can be used to protect ⁇ -cells or pancreas.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can also be used in combination with other therapeutic agents for diabetes, therapeutic agents for diabetic complications, therapeutic agents for hyperlipidemia, therapeutic agents for hypertension and the like.
- a pharmaceutical composition containing a compound of the present invention or a pharmaceutically acceptable salt thereof is systemically or when administered to a mammal (eg, human, horse, cow, pig, etc., preferably human). It can be administered topically, orally or parenterally.
- a mammal eg, human, horse, cow, pig, etc., preferably human. It can be administered topically, orally or parenterally.
- the pharmaceutical composition of the present invention can be prepared by selecting an appropriate form according to the administration method and preparing various preparations usually used.
- oral pharmaceutical composition examples include tablets, pills, powders, granules, capsules, solutions, suspensions, emulsions, syrups, elixirs and the like.
- the pharmaceutical composition in such a form comprises excipients, binders, disintegrants, lubricants, swelling agents, swelling aids, coating agents, plasticizers, stabilizers, preservatives, antioxidants that are usually used as additives.
- Coloring agents, solubilizers, suspending agents, emulsifiers, sweeteners, preservatives, buffers, diluents, wetting agents, and the like may be appropriately selected as necessary and produced according to conventional methods.
- parenteral pharmaceutical composition examples include injections, ointments, gels, creams, poultices, patches, sprays, inhalants, sprays, eye drops, nasal drops, suppositories, and the like.
- the pharmaceutical composition in such a form includes stabilizers, preservatives, solubilizers, moisturizers, preservatives, antioxidants, flavoring agents, gelling agents, neutralizing agents, buffering agents, which are usually used as additives. Isotonic agents, surfactants, colorants, buffering agents, thickeners, wetting agents, fillers, absorption enhancers, suspending agents, binders, etc. are appropriately selected as necessary and manufactured according to conventional methods. Can be done.
- the dose of the compound of the present invention or a pharmaceutically acceptable salt thereof varies depending on symptoms, age, body weight, etc. In the case of oral administration, it is 1 to several times a day, once per adult, as a compound.
- the amount is 1 to 2000 mg, preferably 1 to 400 mg, and in the case of parenteral administration, the amount is 0.01 to 500 mg, preferably 0.1 to 300 mg in terms of compound per adult once or several times a day.
- Methyl 4-amino-2-fluorobenzoate (Bioorg. Med. Chem. 2009, 17, 7042-7051.) (13.0 g, 76.9 mmol) was suspended in 3N hydrochloric acid aqueous solution (108 mL), and nitrous acid under ice-cooling A solution of sodium (5.57 g, 80.7 mmol) in water (25 mL) was added over 10 minutes. After stirring at the same temperature for 30 minutes, the reaction mixture was poured into a mixed suspension of sodium acetate (82.0 g) and ethyl 3-dimethylaminoacrylate (14.3 mL) in water (412 mL) and ethanol (52 mL). Added over 5 minutes under cold.
- Methyl magnesium bromide (0.99 mol / L tetrahydrofuran solution, 34.6 mL, 34.3 mmol) was added dropwise to a suspension of the compound obtained in Reference Example 3 (6.60 g, 21.4 mmol) in tetrahydrofuran (132 mL) under ice cooling. . After stirring at the same temperature for 1 hour, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (dichloromethane) to obtain the title compound (4.63 g, yield: 82%).
- the component obtained by purifying the obtained residue by silica gel column chromatography (15% -25% ethyl acetate / hexane) was diluted with toluene (2.90 mL), and lipase (same as above) (24.0 mg) at room temperature. ), And vinyl acetate (0.0722 mL, 0.781 mmol). After stirring at room temperature for 67 hours, the solid in the reaction solution was filtered off. The solvent of the obtained filtrate was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (15% -25% ethyl acetate / hexane) to give the title compound (0.179 g, yield: 49%).
- N, N-dimethylformamide di-tert-butylacetal (16.4 mL, 68.4 mmol) was added to a suspension of the compound (3.01 g) obtained in Reference Example 18 in dichloromethane (60 mL) at room temperature. After stirring at room temperature for 2.5 hours, the solvent in the reaction solution was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (dichloromethane) to obtain the title compound (2.64 g, yield: 76%).
- 1 H-NMR 400MHz, CDCl 3 ) ⁇ ppm: 8.26 (1H, s), 8.06-7.91 (3H, m), 2.71 (3H, s), 1.63 (9H, s).
- reaction solution A methyl 4-amino-2-fluorobenzoate (Bioorg. Med. Chem.
- the obtained compound was dissolved in tetrahydrofuran (4 mL) and methanol (4 mL), 2M aqueous sodium hydroxide solution (0.765 mL, 1.53 mmol) was added, and the mixture was stirred at room temperature for 30 min. Water and saturated aqueous ammonium chloride solution were added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate and dried over anhydrous sodium sulfate.
- reaction solution was concentrated under reduced pressure, water was added, the aqueous layer was washed with diethyl ether, and 1M sulfuric acid was added to adjust the liquidity to pH 6, followed by extraction twice with ethyl acetate. The layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was washed with a hexane-diisopropyl ether (2: 1, v / v) mixture to obtain the title compound (904 mg, yield: 58%).
- reaction solution was concentrated under reduced pressure, water was added, the aqueous layer was washed with diethyl ether, and 2M hydrochloric acid was added to adjust the liquidity to acidic, followed by extraction twice with ethyl acetate, and the resulting organic layer was washed with saturated brine, and dried over anhydrous sodium sulfate.
- the solvent was distilled off under reduced pressure, and the resulting residue was washed with hexane to obtain the title compound (4.36 g, yield: 100%).
- Triphenylphosphine (57.4 mg) was added to a solution of the compound obtained in Reference Example 69 (70.5 mg, 0.219 mmol) and the compound obtained in Reference Example 66 (40.0 mg, 0.199 mmol) in tetrahydrofuran (1.0 mL) at 0 ° C. 0.219 mmol) and di-tert-butyl azodicarboxylate (50.4 mg, 0.219 mmol) were added, and the mixture was stirred at the same temperature for 10 minutes, and further stirred at room temperature for 3 hours.
- the reaction mixture was cooled to room temperature, water was added, and the mixture was extracted twice with ethyl acetate.
- the obtained organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over anhydrous sodium sulfate.
- Triphenylphosphine (243 mg, 0.927) was added to a solution of the compound (200 mg, 0.843 mmol) obtained in Reference Example 73 and cyclopropyl (4-hydroxyphenyl) methanone (150 mg, 0.927 mmol) in tetrahydrofuran (4.2 mL) at 0 ° C. mmol) and di-tert-butyl azodicarboxylate (214 mg, 0.927 mmol) were added, and the mixture was stirred at the same temperature for 5 minutes, and further stirred at room temperature for 1.5 hours.
- the solvent was distilled off under reduced pressure, and the resulting residue (1.44 g) was dissolved in tetrahydrofuran (7.0 mL) -methanol (7.0 mL), and 1M aqueous sodium hydroxide solution (6.93 mL, 6.93 mmol) was added at room temperature, The mixture was stirred at the same temperature for 30 minutes.
- the reaction solution was concentrated under reduced pressure, water was added, the aqueous layer was washed with diethyl ether, and 1M sulfuric acid was added to adjust the liquidity to pH 6, followed by extraction twice with ethyl acetate. The layer was washed with saturated brine and dried over anhydrous sodium sulfate.
- the reaction mixture was cooled to room temperature, water was added, and the mixture was extracted twice with ethyl acetate.
- the obtained organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over anhydrous sodium sulfate.
- reaction solution was cooled to room temperature, water was added, and the mixture was extracted once with acetone.
- the obtained compound was dissolved in water (45 mL), 5M aqueous sodium hydroxide solution (8.78 mL, 44.4 mmol) was added at room temperature, and the mixture was stirred at the same temperature for 2 hr.
- reaction solution was concentrated under reduced pressure, water was added, the aqueous layer was washed with diethyl ether, and 1M sulfuric acid was added to adjust the liquidity to pH 6, followed by extraction twice with ethyl acetate. The layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was washed with a hexane-diisopropyl ether (10: 1, v / v) mixture to obtain the title compound (364 mg, yield: 83%).
- Triphenylphosphine (188 mg, 0.714 mmol) in a tetrahydrofuran solution (6 ml) of the compound (210 mg, 0.650 mmol) obtained in Reference Example 101 and cyclopropyl (4-hydroxyphenyl) methanone (105 mg, 0.650 mmol) at room temperature.
- di-tert-butyl azodicarboxylate (165 mg, 0.714 mmol) was added, and the mixture was stirred at the same temperature for 30 minutes.
- N ', 4-dihydroxybenzenecarboxyimidamide (WO2011016469) (10.0 g, 65.7 mmol) in N, N-dimethylformamide (100 mL) at 0 ° C. with pyridine (15.9 mL, 197 mmol) and trifluoroacetic anhydride (10.1 mL, 72.6 mmol) was added and stirred at 0 ° C. for 15 minutes. Thereafter, the temperature was raised to 80 ° C. and stirred for 2 hours. The reaction mixture was cooled to room temperature, water and 2M hydrochloric acid were added, and the mixture was extracted twice with ethyl acetate.
- Example 1 4- ⁇ 4-[(1R) -1- ⁇ [6- (cyclopropylcarbonyl) pyridin-3-yl] oxy ⁇ ethyl] -2H-1,2,3-triazol-2-yl ⁇ -N-[(1R, 2R) -2,3-Dihydroxy-1-methylpropyl] -2-fluorobenzamide
- Example 3 (4- ⁇ 4-[(1R) -1- ⁇ [6- (Cyclopropylcarbonyl) pyridin-3-yl] oxy ⁇ ethyl] -2H-1,2,3-triazole- 2-yl ⁇ -2-fluorophenyl) -3- (2-hydroxyethyl) urea
- Triphosgene (75.9 mg, 0.256 mmol) was added to a solution of the compound obtained in Reference Example 28 (188 mg, 0.512 mmol) and N, N-diisopropylethylamine (0.174 mL, 1.02 mmol) in tetrahydrofuran (5 mL) at room temperature. . After stirring at room temperature for 5 minutes, 2-aminoethanol (61.3 ⁇ L, 1.02 mmol) was added. After stirring at room temperature for 4 hours, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate.
- Example 12 4- (5- ⁇ 1- [4- (cyclopropylcarbonyl) phenoxy] propyl ⁇ -2H-tetrazol-2-yl) -2-fluoro-N-[(1R) -2-hydroxy- 1-Methylethyl] benzamide
- Example 15 4- (5- ⁇ 1- [4- (cyclopropylcarbonyl) phenoxy] ethyl ⁇ -1,3-thiazol-2-yl) -2-fluoro-N-[(1R) -2- Hydroxy-1-methylethyl] benzamide
- Example 16 4- [5- (1- ⁇ [6- (cyclopropylcarbonyl) pyridin-3-yl] oxy ⁇ ethyl) -1,3-thiazol-2-yl] -2-fluoro-N— [(1R) -2-hydroxy-1-methylethyl] benzamide
- Example 18 4- [4- (1- ⁇ [6- (Cyclopropylcarbonyl) pyridin-3-yl] oxy ⁇ ethyl) -1,3-oxazol-2-yl] -2-fluoro-N— [(1R) -2-hydroxy-1-methylethyl] benzamide
- Example 20 1- ⁇ 4- [4- (1- ⁇ [6- (Cyclopropylcarbonyl) pyridin-3-yl] oxy ⁇ ethyl) -1,3-oxazol-2-yl] -2-fluoro Phenyl ⁇ -3- (2-hydroxyethyl) urea
- Example 26 4- ⁇ 5-[(1R) -1- ⁇ [6- (cyclopropylcarbonyl) pyridin-3-yl] oxy ⁇ ethyl] -1,2,4-oxadiazol-3-yl ⁇ -2-Fluoro-N-[(1R) -2-hydroxy-1-methylethyl] benzamide
- Example 32 1- ⁇ 4- [5- (1- ⁇ [6- (Cyclopropylcarbonyl) pyridin-3-yl] oxy ⁇ ethyl) -1,2,4-oxadiazol-3-yl] -2-Fluorophenyl ⁇ -3- (2-hydroxyethyl) urea
- Example 42 4- [3- (1- ⁇ [6- (Cyclopropylcarbonyl) pyridin-3-yl] oxy ⁇ ethyl) -1,2,4-oxadiazol-5-yl] -2- Fluoro-N- [2-hydroxy-1- (hydroxymethyl) ethyl] benzamide
- Example 43 1- ⁇ 4- [3- (1- ⁇ [6- (Cyclopropylcarbonyl) pyridin-3-yl] oxy ⁇ ethyl) -1,2,4-oxadiazol-5-yl] -2-Fluorophenyl ⁇ -3- (2-hydroxyethyl) urea
- a compound is obtained by mixing 5 g of the compound obtained in Examples, 90 g of lactose, 34 g of corn starch, 20 g of crystalline cellulose and 1 g of magnesium stearate with a blender, and then tableting with a tableting machine.
- mice Animal oGTT (oral glucose tolerance test) test
- the compound administration solution is a 0.5 w / v% methylcellulose solution, and a suspension is prepared so as to have a concentration of 1 mg / mL while being pulverized in an agate mortar. did.
- Animals received male C57 / BL6J mice (Nippon Charles River Co., Ltd.) from 6 to 8 weeks of age and used from 9 to 13 weeks of age. Fasting was started between 17:00 and 18:00 the day before the test day, and the test was started under fasting for about 16 to 17 hours. Five animals were used in each group. After blood was collected from the tail vein, the compound suspension was orally administered at 10 mg / kg.
- a 0.5 w / v% methylcellulose solution was administered to the negative control group.
- Blood was collected from the tail vein 25 minutes after oral administration, and 30 w / v% glucose solution was orally administered at 10 mL / kg 30 minutes after oral administration.
- Blood was collected from the tail vein 15 minutes, 30 minutes, 60 minutes, and 120 minutes after the glucose load.
- the collected blood was centrifuged to separate the plasma, and plasma blood glucose level (mg / dL) was measured with Glucoroder-GXT (A & T).
- AUC (mg / dL ⁇ min) was calculated using the blood glucose level 5 minutes before glucose load, 15 minutes, 30, 60 minutes, and 120 minutes after glucose load.
- the AUC average value for each group was calculated, and the AUC reduction rate (%) compared with the negative control group was calculated as an index of drug efficacy.
- the compound administration solution prepared by the above-mentioned method is orally administered to the rat at 1 to 5 mL / kg, and 30 to 30 minutes later, the 25 to 50 w / v% glucose solution is orally administered at 4 to 5 mL / kg.
- Blood is collected from the rat tail vein before compound administration, 5 minutes before glucose administration, and 30, 60, 120 and 180 minutes after glucose administration. The obtained blood is centrifuged, the plasma is separated, and the plasma blood glucose level is measured with Glucoroder-GXT (A & T). The AUC of the blood glucose level after glucose administration in each group is calculated, and the reduction rate (%) with respect to the blood glucose level AUC in the vehicle administration group is expressed as the efficacy of the compound.
- the plasma obtained by the above method is used for measuring the blood concentration of the test compound.
- blood is also collected from 4 to 8 hours and 24 hours after administration.
- the concentration of the compound in the blood is calculated using a liquid chromatography / mass spectrometer.
- the compound of the present invention or a pharmaceutically acceptable salt thereof treats and / or treats type 1 diabetes, type 2 diabetes, gestational diabetes, hyperglycemia due to other factors, glucose intolerance, diabetes related diseases, diabetic complications and the like. Or, for prevention, it is useful as an active ingredient of a pharmaceutical composition for protecting ⁇ cells or pancreas.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
(1)一般式(I):
(2)環Aが、
(3)環Aが
(4)環Aが、
(5)環Aが、
(6)環Aが、
(7)一般式(II):
(8)一般式(III):
(9)以下:
1-[4-(4-{1-[4-(シクロプロピルカルボニル)フェノキシ]プロピル}-2H-1,2,3-トリアゾール-2-イル)-2-フルオロフェニル]-3-(2-ヒドロキシエチル)ウレア;
4-{4-[(1R)-1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル]-2H-1,2,3-トリアゾール-2-イル}-N-[(1R,2R)-2,3-ジヒドロキシ-1-メチルプロピル]-2-フルオロベンズアミド;
1-(4-{4-[(1R)-1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル]-2H-1,2,3-トリアゾール-2-イル}-2-フルオロフェニル)-3-(2-ヒドロキシエチル)ウレア;
4-(5-{1-[4-(シクロプロピルカルボニル)フェノキシ]プロピル}-2H-テトラゾール-2-イル)-2-フルオロ-N-[(1R)-2-ヒドロキシ-1-メチルエチル]ベンズアミド;
4-(5-{1-[4-(シクロプロピルカルボニル)フェノキシ]エチル}-1,3-チアゾール-2-イル)-2-フルオロ-N-[(1R)-2-ヒドロキシ-1-メチルエチル]ベンズアミド;
4-[4-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,3-オキサゾール-2-イル]-2-フルオロ-N-[(1R)-2-ヒドロキシ-1-メチルエチル]ベンズアミド;
N-シクロプロピル-4-[4-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,3-オキサゾール-2-イル]-2-フルオロベンズアミド;
1-{4-[4-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,3-オキサゾール-2-イル]-2-フルオロフェニル}-3-(2-ヒドロキシエチル)ウレア;
4-{5-[(1R)-1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル]-1,2,4-オキサジアゾール-3-イル}-2-フルオロ-N-[(1R)-2-ヒドロキシ-1-メチルエチル]ベンズアミド;
1-{4-[5-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,2,4-オキサジアゾール-3-イル]-2-フルオロフェニル}-3-(2-ヒドロキシエチル)ウレア;
4-[3-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,2,4-オキサジアゾール-5-イル]-2-フルオロ-N-[2-ヒドロキシ-1-(ヒドロキシメチル)エチル]ベンズアミド;および
1-{4-[3-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,2,4-オキサジアゾール-5-イル]-2-フルオロフェニル}-3-(2-ヒドロキシエチル)ウレア
からなる群より選択される化合物またはその薬学的に許容され得る塩;
(10)前記(1)~(9)いずれか1項に記載の化合物またはその薬学的に許容され得る塩を有効成分として含有する医薬組成物;
(11)1型糖尿病、2型糖尿病または肥満を治療するための、前記(10)に記載の医薬組成物;
(12)β細胞または膵臓を保護するための、前記(10)に記載の医薬組成物;
(13)医薬組成物を製造するための、前記(1)~(9)いずれか1項に記載の化合物またはその薬学的に許容され得る塩の使用;
(14)前記(1)~(9)いずれか1項に記載の化合物またはその薬学的に許容され得る塩を哺乳動物に投与することを含む、疾病を治療する方法;ならびに
(15)哺乳動物がヒトである前記(14)に記載の方法;
を提供する。
1H-NMR (400MHz, CDCl3) δppm:
8.27 (1H, s), 8.13-7.98 (3H, m), 4.49 (2H, q, J = 7 Hz), 3.97 (3H, s), 1.45 (3H, t, J = 7 Hz).
1H-NMR (400MHz, DMSO-d6) δppm:
13.80 (1H, m), 8.63 (1H, s), 8.16-7.92 (3H, m), 3.90 (3H, s).
1H-NMR (400MHz, CDCl3) δppm:
8.25 (1H, s), 8.13-7.95 (3H, m), 3.97 (3H, s), 3.85 (3H, s), 3.46 (3H, br s).
1H-NMR (400MHz, CDCl3) δppm:
8.27 (1H, s), 8.14-8.10 (1H, m), 8.02-7.95 (2H, m), 3.98 (3H, s), 3.16-3.11 (2H, m), 1.29-1.25 (3H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.09-8.05 (1H, m), 7.93-7.85 (2H, m), 7.81 (1H, s), 4.94-4.89 (1H, m), 3.96 (3H, s), 2.20-2.19 (1H, m), 2.01-1.88 (2H, m), 1.05-1.02 (3H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.10-8.06 (1H, m), 7.98-7.86 (4H, m), 7.76 (1H, s), 7.01-6.99 (2H, m), 5.52-5.49 (1H, m), 3.96 (3H, s), 2.62-2.56 (1H, m), 2.21-2.07 (2H, m), 1.20-1.17 (2H, m), 1.10-1.06 (3H, m), 1.00-0.97 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.19-8.15 (1H, m), 7.99-7.89 (4H, m), 7.78 (1H, s), 7.03-6.99 (2H, m), 5.53-5.50 (1H, m), 2.63-2.56 (1H, m), 2.22-2.06 (2H, m), 1.21-1.17 (2H, m), 1.11-1.07 (3H, m), 1.01-0.96 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.26 (1H, s), 8.15-8.11 (1H, m), 8.03-7.95 (2H, m), 3.98 (3H, s), 2.71 (3H, s).
1H-NMR (400MHz, CDCl3) δppm:
8.10-8.05 (1H, m), 7.93-7.86 (2H, m), 7.83 (1H, s), 5.19-5.12 (1H, m), 3.96 (3H, s), 1.65 (3H, d, J = 7 Hz).
1H-NMR (400MHz, CDCl3) δppm:
8.10-8.06 (1H, m), 7.99-7.97 (2H, m), 7.93-7.86 (2H, m), 7.80 (1H, s), 7.04-7.00 (2H, m), 5.77-5.73 (1H, m), 3.96 (3H, s), 2.63-2.57 (1H, m), 1.80 (3H, d, J = 7 Hz), 1.21-1.18 (2H, m), 1.01-0.96 (2H, m).
1H-NMR (400MHz, DMSO-d6) δppm:
8.32 (1H, s), 8.12-8.01 (3H, m), 7.94-7.85 (2H, m), 7.18-7.16 (2H, m), 6.02-5.97 (1H, m), 2.87-2.80 (1H, m), 1.75 (3H, d, J = 6 Hz), 0.98-0.96 (4H, m).
1H-NMR (400MHz, DMSO-d6) δppm:
13.54 (1H, br s), 8.67 (1H, s), 8.15-8.11 (1H, m), 8.04-7.97 (2H, m), 3.16-3.10 (2H, m), 1.15-1.12 (3H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.26 (1H, s), 8.06-8.02 (1H, m), 7.98-7.90 (2H, m), 3.14 (2H, q, J = 7 Hz), 1.62 (9H, s), 1.27 (3H, t, J = 7 Hz).
1H-NMR (400MHz, CDCl3) δppm:
8.00-7.96 (1H, m), 7.89-7.81 (3H, m), 7.80 (3H, s), 4.93-4.89 (1H, m), 2.21-2.20 (1H, m), 2.01-1.88 (2H, m), 1.61 (9H, s), 1.06-1.02 (3H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.00-7.96 (1H, m), 7.89-7.81 (3H, m), 7.80 (3H, s), 4.93-4.89 (1H, m), 2.17-2.16 (1H, m), 2.00-1.90 (2H, m), 1.62 (9H, s), 1.06-1.02 (3H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.02-7.94 (3H, m), 7.89-7.81 (2H, m), 7.75 (1H, s), 7.03-6.99 (2H, m), 5.52-5.49 (1H, m), 2.62-2.56 (1H, m), 2.21-2.07 (2H, m), 1.62 (9H, s), 1.20-1.17 (2H, m), 1.10-1.07 (3H, m), 1.00-0.96 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.19-8.15 (1H, m), 7.99-7.89 (4H, m), 7.78 (1H, s), 7.03-6.99 (2H, m), 5.53-5.50 (1H, m), 2.63-2.56 (1H, m), 2.22-2.06 (2H, m), 1.21-1.17 (2H, m), 1.11-1.07 (3H, m), 1.01-0.96 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.26 (1H, s), 8.15-8.11 (1H, m), 8.03-7.95 (2H, m), 3.98 (3H, s).
1H-NMR (400MHz, CDCl3) δppm:
8.26 (1H, s), 8.06-7.91 (3H, m), 2.71 (3H, s), 1.63 (9H, s).
1H-NMR (400MHz, CDCl3) δppm:
8.01-7.97 (1H, m), 7.89-7.81 (3H, m), 5.18-5.12 (1H, m), 1.65 (3H, d, J = 6 Hz), 1.62 (9H, s).
1H-NMR (400MHz, CDCl3) δppm:
1H-NMR (CDCl3) δ: 8.01-7.97 (1H, m), 7.89-7.81 (3H, m), 5.18-5.12 (1H, m), 1.65 (4H, d, J = 6.4 Hz), 1.62 (9H, s).
1H-NMR (400MHz, CDCl3) δppm:
8.46 (1H, dd, J = 3, 1 Hz), 7.65 (1H, dd, J = 9, 1 Hz), 7.45 (1H, dd, J = 9, 3 Hz), 5.28 (2H, s), 3.50 (3H, s).
1H-NMR (400MHz, CDCl3) δppm:
8.32 (1H, dd, J = 3, 1 Hz), 8.00 (1H, d, J = 9, 1 Hz), 7.27 (1H, dd, J = 9, 3 Hz), 3.43-3.35 (1H, m), 1.26-1.21 (2H, m), 1.12-1.06 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.42 (1H, d, J = 3 Hz), 8.02-7.98 (2H, m), 7.89-7.81 (3H, m), 7.37-7.34 (1H, m), 5.81-5.76 (1H, m), 3.45-3.38 (1H, m), 1.84 (3H, d, J= 7 Hz), 1.62 (9H, s), 1.22-1.18 (2H, m), 1.08-1.03 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.45 (1H, d, J = 3 Hz), 8.18-8.14 (1H, m), 8.01 (1H, d, J= 9 Hz), 7.97-7.89 (2H, m), 7.85 (1H, s), 7.38-7.35 (1H, m), 5.83-5.78 (1H, m), 3.43-3.37 (1H, m), 1.85 (3H, d, J= 6 Hz), 1.22-1.19 (2H, m), 1.09-1.04 (2H, m).
上記の混合物(0.610g)のジクロロメタン(12mL)溶液に、室温にてトリフルオロ酢酸(6mL)を加えた。室温にて2時間攪拌後、反応液中の溶媒を減圧下、留去した。得られた残渣に飽和炭酸水素ナトリウム水溶液および水を加え、ジクロロメタンで抽出した。得られた有機層を無水硫酸ナトリウムで乾燥した。ろ別後、減圧下溶媒を留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(25% 酢酸エチル/ヘキサン)で精製することにより、標記化合物(242mg、収率:52%)を得た。
1H-NMR (400MHz, CDCl3) δppm:
7.97-7.93 (2H, m), 7.72-7.69 (1H, m), 7.64-7.61 (2H, m), 7.03-6.99 (2H, m), 6.86-6.82 (1H, m), 5.49-5.45 (1H, m), 3.85 (2H, br s), 2.62-2.56 (1H, m), 2.20-2.04 (2H, m), 1.20-1.16 (2H, m), 1.09-1.05 (3H, m), 1.00-0.95 (2H, m).
上記の混合物(0.282g)のジクロロメタン(6mL)溶液に、室温にてトリフルオロ酢酸(3mL)を加えた。室温にて1時間攪拌後、反応液中の溶媒を減圧下、留去した。得られた残渣に飽和炭酸水素ナトリウム水溶液および水を加え、ジクロロメタンで抽出した。得られた有機層を無水硫酸ナトリウムで乾燥した。ろ別後、減圧下溶媒を留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(30% 酢酸エチル/ヘキサン)で精製することにより、標記化合物(190mg、収率:99%)を得た。
1H-NMR (400MHz, CDCl3) δppm:
8.42 (1H, d, J = 3 Hz), 8.00-7.98 (1H, m), 7.72-7.68 (2H, m), 7.64-7.61 (1H, m), 7.39-7.36 (1H, m), 6.87-6.83 (1H, m), 5.78-5.73 (1H, m), 3.44-3.37 (1H, m), 1.82 (3H, d, J = 6 Hz), 1.21-1.18 (2H, m), 1.08-1.03 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.22-8.18 (1H, m), 8.13-8.06 (2H, m), 4.62-4.57 (2H, m), 3.99 (3H, s), 1.52-1.49 (3H, m).
1H-NMR (400MHz, DMSO-d6) δppm:
8.23-8.10 (3H, m), 3.92 (3H, s).
1H-NMR (400MHz, CDCl3) δppm:
8.21-8.18 (1H, m), 8.11-8.02 (2H, m), 3.99 (3H, s), 3.93 (3H, s), 3.46 (3H, br s).
1H-NMR (400MHz, CDCl3) δppm:
8.22-8.18 (1H, m), 8.13-8.06 (2H, m), 4.00 (3H, s), 3.30-3.25 (2H, m), 1.34-1.31 (3H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.18-8.14 (1H, m), 8.05-7.97 (2H, m), 5.11-5.06 (1H, m), 3.99 (3H, s), 2.65-2.63 (1H, m), 2.18-1.99 (2H, m), 1.08-1.05 (3H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.17-8.13 (1H, m), 8.03-7.95 (4H, m), 7.08-7.05 (2H, m), 5.67-5.64 (1H, m), 3.98 (3H, s), 2.62-2.56 (1H, m), 2.38-2.21 (2H, m), 1.20-1.16 (2H, m), 1.13-1.09 (3H, m), 1.00-0.97 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.25-8.21 (1H, m), 8.06-7.96 (4H, m), 7.08-7.06 (2H, m), 5.68-5.65 (1H, m), 2.62-2.56 (1H, m), 2.39-2.22 (2H, m), 1.21-1.17 (2H, m), 1.13-1.10 (3H, m), 1.00-0.97 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.23-8.06 (3H, m), 4.00 (3H, s), 2.86 (3H, s).
1H-NMR (400MHz, CDCl3) δppm:
8.19-8.15 (1H, m), 8.05-7.97 (2H, m), 5.34-5.28 (1H, m), 3.99 (3H, s), 1.76 (3H, d, J = 7 Hz).
1H-NMR (400MHz, CDCl3) δppm:
8.47-8.46 (1H, m), 8.18-8.14 (1H, m), 8.03-7.95 (3H, m), 7.45-7.42 (1H, m), 5.96-5.91 (1H, m), 3.98 (3H, s), 3.45-3.38 (1H, m), 1.97 (3H, d, J = 7 Hz), 1.21-1.18 (2H, m), 1.08-1.03 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.49 (1H, d, J = 3 Hz), 8.24-8.20 (1H, m), 8.06-7.98 (3H, m), 7.45 (1H, dd, J = 9, 3 Hz), 5.97-5.92 (1H, m), 3.42-3.36 (1H, m), 1.98 (3H, d, J = 7 Hz), 1.23-1.19 (2H, m), 1.09-1.04 (2H, m).
1H-NMR (500MHz, DMSO-d6) δppm:
10.21 (1H, s), 9.75 (1H, s), 7.94-7.90 (1H, m), 7.79-7.72 (2H, m), 3.88-3.87 (3H, m).
1H-NMR (500MHz, DMSO-d6) δppm:
10.12 (1H, m), 8.86-8.85 (1H, m), 8.05-8.02 (3H, m), 3.90-3.89 (3H, m).
1H-NMR (500MHz, CDCl3) δppm:
8.01-7.98 (1H, m), 7.73-7.71 (3H, m), 5.25-5.20 (1H, m), 3.96-3.95 (3H, m), 2.34-2.32 (1H, m), 1.67-1.65 (3H, m).
1H-NMR (500MHz, CDCl3) δppm:
8.01-7.96 (3H, m), 7.82 (1H, m), 7.72-7.71 (1H, m), 7.70-7.69 (1H, m), 7.02-6.98 (2H, m), 5.81-5.77 (1H, m), 3.95 (3H, s), 2.63-2.57 (1H, m), 1.83 (3H, d, J = 6 Hz), 1.21-1.18 (2H, m), 1.02-0.97 (2H, m).
1H-NMR (400MHz, DMSO-d6) δppm:
13.44 (1H, br s), 8.10 (1H, s), 8.02-7.93 (3H, m), 7.83-7.79 (2H, m), 7.19-7.15 (2H, m), 6.20-6.15 (1H, m), 2.86-2.80 (1H, m), 1.75-1.74 (3H, m), 0.98-0.96 (4H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.40 (1H, d, J = 3 Hz), 8.03-7.97 (2H, m), 7.84 (1H, s), 7.73-7.69 (2H, m), 7.32 (1H, dd, J = 9, 3 Hz), 5.82 (1H, q, J = 6 Hz), 3.95 (3H, s), 3.45-3.37 (1H, m), 1.86 (4H, d, J = 6 Hz), 1.22-1.17 (2H, m), 1.09-1.03 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
10.03 (1H, s), 7.94 (2H, d, J = 9 Hz), 7.31 (2H, d, J = 9 Hz), 7.26 (1H, s), 2.54 (3H, s).
1H-NMR (500MHz, CDCl3) δppm:
7.83 (2H, d, J = 9 Hz), 7.64 (1H, s), 7.28 (2H, d, J = 9 Hz), 4.90 (1H, dd, J = 7, 6 Hz), 2.52 (3H, s), 2.18 (1H, br s), 1.97-1.84 (2H, m), 1.00 (3H, t, J = 7 Hz).
1H-NMR (500MHz, CDCl3) δppm:
7.73 (1H, dd, J = 9, 1 Hz), 7.66 (1H, dd, J = 8, 1 Hz), 7.61 (1H, dd, J = 8, 6 Hz), 4.95 (1H, dd, J = 11, 8 Hz), 4.72 (1H, dd, J = 9, 8 Hz), 4.62 (1H, dd, J = 11, 9 Hz), 3.83 (3H, s).
1H-NMR (400MHz, CDCl3) δppm:
8.31 (1H, s), 7.87 (1H, dd, J = 9, 2 Hz), 7.80 (1H, td, J = 8, 2 Hz), 7.68 (1H, dd, J = 8, 7 Hz), 3.97 (3H, s).
1H-NMR (500MHz, CDCl3) δppm:
7.78 (1H, dd, J = 9, 2 Hz), 7.71 (1H, dd, J = 8, 2 Hz), 7.68 (1H, s), 7.65 (1H, dd, J = 8, 7 Hz), 4.69 (2H, d, J = 6 Hz), 2.06 (1H, br s).
1H-NMR (500MHz, CDCl3) δppm:
7.78 (1H, dd, J = 9, 2 Hz), 7.71 (1H, dd, J = 8, 2 Hz), 7.64 (1H, dd, J = 8, 7 Hz), 7.61 (1H, s), 4.95-4.88 (1H, m), 2.27 (1H, br s), 1.58 (3H, d, J = 6 Hz).
1H-NMR (500MHz, CDCl3) δppm:
8.03 (1H, dd, J = 8, 7 Hz), 7.87 (1H, dd, J = 8, 1 Hz), 7.81 (1H, dd, J = 11, 1 Hz), 7.65 (1H, s), 4.97-4.90 (1H, m), 3.96 (3H, s), 2.27 (1H, d, J = 5 Hz), 1.59 (3H, d, J= 8 Hz).
1H-NMR (400MHz, CDCl3)δppm:
8.18-8.05 (1H, m), 8.00 (2H, d, J = 9 Hz), 7.95-7.80 (2H, m), 7.66 (1H, s), 7.02 (2H, d, J = 9 Hz), 5.55 (1H, q, J = 6 Hz), 2.66-2.57 (1H, m), 1.76 (3H, d, J= 7 Hz), 1.23-1.18 (2H, m), 1.03-0.98 (2H, m).
1H-NMR (500MHz, CDCl3) δppm:
8.45 (1H, d, J = 3 Hz), 8.12 (1H, dd, J = 8, 7 Hz), 8.02 (1H, d, J = 9 Hz), 7.90 (1H, dd, J = 8, 2 Hz), 7.84 (1H, dd, J = 11, 2 Hz), 7.71 (1H, d, J = 1 Hz), 7.37 (1H, dd, J = 9, 3 Hz), 5.58 (1H, q, J = 7 Hz), 3.45-3.37 (1H, m), 1.81 (3H, d, J = 7 Hz), 1.24-1.19 (2H, m), 1.10-1.04 (2H, m).
1H-NMR (400MHz, CDCl3)δppm:
7.98 (2H, d, J = 9 Hz), 7.67-7.61 (2H, m), 7.51 (1H, s), 7.02 (2H, d, J = 7 Hz), 6.81 (1H, dd, J = 9, 8 Hz), 5.52 (1H, q, J = 6 Hz), 3.27 (2H, bs), 2.64-2.56 (1H, m), 1.74 (3H, d, J= 6 Hz), 1.22-1.18 (2H, m), 1.02-0.96 (2H, m).
1H-NMR (400MHz, CDCl3)δppm:
8.49-8.48 (1H, m), 8.02 (1H, d, J = 9 Hz), 7.65-7.60 (2H, m), 7.57 (1H, s), 7.43-7.39 (1H, m), 6.81 (1H, dd, J = 9, 9 Hz), 5.57 (1H, q, J = 6 Hz), 3.45-3.38 (1H, m), 1.78 (3H, d, J = 6 Hz), 1.25-1.20 (2H, m), 1.10-1.06 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
7.97 (1H, t, J = 8 Hz), 7.90 (1H, d, J = 8 Hz), 7.84 (1H, d, J = 5 Hz), 5.18 (1H, q, J = 7 Hz), 1.73 (4H, d, J = 7 Hz), 1.60 (9H, s);
MS (FAB) m/z: 309 [M+H]+.
1H-NMR (400MHz, CDCl3) δppm:
8.48 (1H, d, J = 3 Hz), 8.13 (1H, dd, J = 8, 7 Hz), 8.04 (1H, d, J = 9 Hz), 7.95 (1H, dd, J = 8, 2 Hz), 7.90 (1H, dd, J = 11, 2 Hz), 7.40 (1H, dd, J = 9, 3 Hz), 5.80 (1H, q, J = 7 Hz), 3.44-3.37 (1H,m), 1.97 (3H, d, J = 7 Hz), 1.24-1.19 (2H, m), 1.11-1.05 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.31 (1H, d, J = 3 Hz), 8.00 (1H, d, J = 9 Hz), 7.31 (1H, dd, J = 9, 3 Hz), 4.05-3.98 (1H, m), 1.20 (6H, d, J = 7 Hz).
1H-NMR (400MHz, CDCl3) δppm:
8.35 (1H, d, J = 3 Hz), 8.05 (1H, d, J = 9 Hz), 7.26 (1H, d, J = 9, 3 Hz), 4.74 (1H, dd, J = 7, 5 Hz), 4.04-3.95 (1H, m), 2.17-2.03 (2H, m), 1.19 (6H, d, J = 7 Hz), 1.14 (3H, t, J = 7 Hz).
1H-NMR (500MHz, CDCl3) δppm:
8.42 (1H, d, J = 3 Hz), 8.05 (1H, dd, J = 8, 7 Hz), 8.03 (1H, d, J= 9 Hz), 7.92 (1H, dd, J = 8, 2 Hz), 7.86 (1H, dd, J = 11, 2 Hz), 7.36 (1H, dd, J = 9, 3 Hz), 5.54 (1H, dd, J = 7, 6 Hz), 4.07-4.00 (1H, m), 3.97 (3H, s), 2.38-2.24 (2H, m), 1.18 (6H, d, J = 7 Hz), 1.16 (3H, t, J = 7 Hz).
1H-NMR (500MHz, CDCl3) δppm:
8.45 (1H, d, J = 3 Hz), 8.14 (1H, dd, J = 8, 7 Hz), 8.05 (1H, d, J = 9 Hz), 7.96 (1H, dd, J = 8, 1 Hz), 7.90 (1H, dd, J = 11, 1 Hz), 7.38 (1H, dd, J = 9, 3 Hz), 5.56 (1H, dd, J = 7, 6 Hz), 4.08-3.98 (1H, m), 2.41-2.23 (2H, m), 1.18 (6H, d, J = 7 Hz), 1.17 (3H, t, J = 7 Hz).
1H-NMR (500MHz, CDCl3) δppm:
8.41 (1H, d, J = 3 Hz), 8.03 (1H, d, J = 9 Hz), 7.44 (1H, dd, J = 9, 3 Hz), 5.27 (2H, s), 3.50 (3H, s), 3.05 (2H, d, J = 7 Hz), 2.36-2.26 (1H, m), 0.99 (6H, d, J = 6 Hz).
1H-NMR (500MHz, CDCl3) δppm:
8.42 (1H, d, J = 3 Hz), 7.56 (1H, d, J = 9 Hz), 7.43 (1H, dd, J = 9, 3 Hz), 5.23 (2H, s), 3.50 (3H, s), 2.22 (2H, td, J = 18, 7 Hz), 1.93-1.84 (1H, m), 0.95 (6H, d, J= 7 Hz).
(500MHz, CDCl3) δppm:
8.27 (1H, d, J = 2 Hz), 7.54 (1H, d, J = 9 Hz), 7.25 (1H, dd, J = 9, 2 Hz), 2.20 (2H, td, J = 18, 7 Hz), 1.92-1.83 (1H, m), 0.94 (6H, d, J = 7 Hz).
1H-NMR (400MHz, CDCl3)δppm:
5.00 (1H, m), 2.15 (3H, s), 1.94-1.90 (2H, m), 1.03 (3H, t, J = 7 Hz);
MS (FAB) m/z: 147 [M+H]+.
1H-NMR (400MHz, CDCl3) δppm:
7.96 (1H, t, J = 8 Hz), 7.90 (1H, dd, J = 8, 2 Hz), 7.84 (1H, dd, J = 11, 2 Hz), 5.92 (1H, t, J = 7 Hz), 2.21 (3H, s), 2.16-2.08 (2H, m), 1.62 (9H, s), 1.05 (3H, t, J = 7 Hz);
MS (FAB) m/z: 365 [M+H]+.
1H-NMR (400MHz, CDCl3) δppm:
7.97 (1H, t, J = 8 Hz), 7.91 (1H, d, J = 8 Hz), 7.85 (1H, d, J = 11 Hz), 4.98 (1H, q, J = 6 Hz), 2.54 (1H, brs), 2.14-1.96 (2H, m), 1.62 (9H, s), 1.08 (3H, t, J = 7 Hz);
MS (FAB+) m/z: 323 [M+H]+.
1H-NMR (400MHz, CDCl3) δppm:
8.46 (1H, d, J = 3 Hz), 8.12 (1H, dd, J = 8, 7 Hz), 7.96 (1H, d, J = 8 Hz), 7.90 (1H, d, J = 11 Hz), 7.58 (1H, d, J = 9 Hz), 7.37 (1H, dd, J = 9, 3 Hz), 5.49 (1H, dd, J = 7, 6 Hz), 2.38-2.13 (4H, m), 1.91-1.82 (1H, m), 1.16 (3H, t, J = 7 Hz), 0.94 (6H, d, J = 7 Hz).
1H-NMR (500MHz, DMSO-d6)δppm:
9.35 (1H, s), 7.27 (1H, dd, J = 13, 2 Hz), 7.21 (1H, dd, J = 8, 2 Hz), 6.71 (1H, dd, J = 9, 8 Hz), 5.63 (2H, s), 5.33 (2H, s).
1H-NMR (500MHz, CDCl3) δppm:
7.74-7.66 (2H, m), 6.82 (1H, dd, J = 9, 8 Hz), 5.90 (1H, dd, J = 7, 6 Hz), 4.03 (1H, s), 2.19 (3H, d, J= 4 Hz), 2.16-2.04 (2H, m), 1.03 (2H, t, J= 8 Hz).
1H-NMR (500MHz, CDCl3) δppm:
7.74-7.66 (2H, m), 6.83 (1H, dd, J = 9, 8 Hz), 4.92 (1H, dd, J = 7, 6 Hz), 4.04 (2H, br s), 2.64 (1H, br s), 2.11-1.93 (2H, m), 1.06 (3H, t, J = 8 Hz).
1H-NMR (500MHz, CDCl3) δppm:
7.98 (2H, d, J = 9 Hz), 7.72-7.65 (2H, m), 7.03 (2H, d, J = 9 Hz), 6.81 (1H, dd, J = 9, 8 Hz), 5.47 (1H, dd, J = 7, 6 Hz), 4.04 (2H, s), 2.62-2.56 (1H, m), 2.33-2.16 (2H, m), 1.22-1.17 (2H, m), 1.12 (3H, t, J = 7 Hz), 1.01-0.96 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.38 (1H, d, J = 3 Hz), 8.03 (1H, d, J = 9 Hz), 7.26 (1H, dd, J = 9, 2 Hz), 4.93 (1H, q, J = 7 Hz), 3.41-3.35 (1H, m), 1.74 (3H, d, J = 7 Hz), 1.25-1.20 (2H, m), 1.10-1.05 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.46 (1H, d, J = 3 Hz), 8.02 (1H, d, J = 9 Hz), 7.69 (1H, dd, J = 12, 2 Hz), 7.67 (1H, dd, J = 8, 2), 7.38 (1H, dd, J = 9, 3 Hz), 6.82 (1H, dd, J = 9, 8 Hz), 5.73 (1H, q, J = 7 Hz), 4.06 (2H, s), 3.46-3.93 (1H, m), 1.93 (3H, d, J = 7 Hz), 1.23-1.19 (2H, m), 1.10-1.04 (2H, m).
1H-NMR (400MHz, CDCl3)δppm:
8.03 (2H, d, J= 9 Hz), 7.76-7.68 (2H, m), 7.10 (2H, d, J= 9 Hz), 6.85 (1H, dd, J = 9, 8 Hz), 5.49 (1H, t, J = 7 Hz), 4.08 (2H, bs), 3.34-3.24 (m, 1H), 2.38-2.20 (2H, m), 1.47 (6H, d, J = 7 Hz), 1.13 (3H, t, J = 8 Hz).
1H-NMR (400MHz, CDCl3)δppm:
8.00 (2H, d, J= 9 Hz), 7.73-7.65 (2H, m), 7.06 (2H, d, J= 9 Hz), 6.81 (1H, dd, J = 9, 8 Hz), 5.46 (1H, t, J = 7 Hz), 3.30-3.19 (m, 1H), 2.32-2.17 (2H, m), 1.43 (6H, d, J= 7 Hz), 1.13 (3H, t, J = 8 Hz).
1H-NMR (400MHz, CDCl3) δppm:
10.0 (1H, d, J = 2 Hz), 8.01 (1H, dd, J = 8, 7 Hz), 7.69 (1H, d, J = 8, 2 Hz), 7.61 (1H, dd, J = 10, 2 Hz), 1.61 (9H, s).
1H-NMR (400MHz, CDCl3) δppm:
7.97-7.89 (2H, m), 7.83 (1H, dd, J = 11, 1 Hz), 1.62 (9H, s).
1H-NMR (400MHz, CDCl3)δppm:
8.01-7.99 (2H, m), 6.95-6.93 (2H, m), 4.88 (2H, q, J = 7 Hz), 2.65-2.59 (1H, m), 1.70 (3H, d, J = 7 Hz), 1.24-1.20 (2H, m), 1.03-1.01 (2H, m).
1H-NMR (400MHz, CDCl3)δppm:
8.06 (2H, d, J= 9 Hz), 7.06 (2H, d, J = 9 Hz), 4.99 (1H, q, J = 7 Hz), 2.67-2.58 (1H, m), 1.84 (3H, d, J= 7 Hz), 1.39-1.32 (2H, m), 1.06-1.01 (2H, m).
1H-NMR (400MHz, CDCl3)δppm:
8.00 (2H, d, J= 9 Hz), 7.06 (2H, d, J = 9 Hz), 4.87 (1H, q, J =7 Hz), 4.68 (2H, bs), 2.64-2.57 (2H, m), 1.64 (3H, d, J = 7 Hz), 1.25-1.18 (2H, m), 1.04-0.98 (2H, m).
1H-NMR (400MHz, CDCl3)δppm:
8.20-8.14 (1H, m), 8.03-7.92 (4H, m), 7.08 (2H, d, J = 9 Hz), 5.72 (1H, q, J = 7 Hz), 2.63-2.56 (1H, m), 1.87 (3H, d, J = 6 Hz), 1.21-1.17 (2H, m), 1.01-0.96 (2H, m).
1H-NMR (400MHz, CDCl3)δppm:
7.98 (2H, d, J = 9 Hz), 7.76-7.72 (2H, m), 7.08 (2H, d, J = 9 Hz), 6.82 (1H, t, J = 9 Hz), 5.66 (1H, q, J = 7 Hz), 2.64-2.57 (1H, m), 1.84 (3H, d, J = 6 Hz), 1.21-1.17 (2H, m), 1.02-0.95 (2H, m).
1H-NMR (400MHz, CDCl3)δppm:
8.02 (2H, d, J= 9 Hz), 6.99 (2H, d, J = 9 Hz), 6.28 (1H, bs), 5.74 (1H, bs), 4.62 (1H, dd, J = 6, 5 Hz), 2.66-2.52 (1H, m), 2.10-1.95 (2H, m), 1.25-1.20 (2H, m), 1.10-1.00 (5H, m).
1H-NMR (400MHz, CDCl3)δppm:
8.05 (2H, d, J = 9 Hz), 7.07 (2H, d, J = 9 Hz), 4.83 (1H, t, J = 6 Hz), 2.67-2.60 (1H, m), 2.19-2.12 (2H, m), 1.28-1.17 (5H, m), 1.06-0.97 (2H, m).
1H-NMR (500MHz, CDCl3)δppm:
7.98 (2H, d, J= 9 Hz), 7.07 (2H, d, J = 9 Hz), 4.70 (2H, s), 4.62-4.55 (1H, m), 3.72 (1H, dq, J = 7, 6 Hz), 2.64-2.53 (1H, m), 2.08-1.82 (2H, m), 1.23-1.17 (2H, m), 1.09-0.92 (5H, m).
1H-NMR (400MHz, CDCl3)δppm:
8.02-7.92 (4H, m), 7.88 (1H, d, J= 9 Hz), 7.08 (2H, d, J = 9 Hz), 5.46 (1H, t, J = 7 Hz), 2.65-2.56 (1H, m), 2.36-2.12 (2H, m), 1.61 (9H, s), 1.23-1.17 (2H, m), 1.11 (3H, t, J = 7 Hz), 1.02-0.96 (2H, m).
1H-NMR (500MHz, CDCl3)δppm:
8.17 (1H, dd, J= 8, 7 Hz), 8.03-7.92 (4H, m), 7.08 (2H, d, J = 9 Hz), 5.47 (1H, t, J= 7 Hz), 2.63-2.56 (1H, m), 2.34-2.10 (2H, m), 1.22-1.15 (2H, m), 1.11 (3H, t, J = 8 Hz), 1.02-0.95 (2H, m).
1H-NMR (400MHz, CDCl3)δppm:
7.995 (2H, d, J = 9 Hz), 7.80-7.73 (2H, m), 7.08 (2H, d, J = 9 Hz), 6.82 (1H, t, J = 9 Hz), 5.39 (1H, t, J = 7 Hz), 4.24 (2H, s), 2.64-2.56 (1H, m), 2.34-2.10 (2H, m), 1.24-1.20 (2H, m), 1.09 (1H, t, J = 7 Hz), 1.04-0.96 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.48 (1H, d, J = 3 Hz), 8.17 (1H, dd, J = 8, 7 Hz), 8.02 (1H, d, J = 9 Hz), 8.01 (1H, dd, J = 8, 2 Hz), 7.95 (1H, dd, J = 10, 2 Hz), 7.43 (1H, dd, J = 9, 3 Hz), 5.75 (1H, q, J = 6.5 Hz), 3.45-3.38 (1H,m), 1.91 (3H, d, J = 7 Hz), 1.22-1.17 (2H,m), 1.09-1.03 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
8.47 (1H, d, J = 3 Hz), 8.34 (1H, t, J = 8 Hz), 8.00 (1H, d, J = 9 Hz), 7.90 (1H, dd, J = 8, 2 Hz), 7.83 (1H, dd, J = 11, 2 Hz), 7.42 (1H, dd, J = 9, 3 Hz), 6.98-6.94 (1H, m), 5.70 (1H, q, J = 7 Hz), 3.45-3.39 (1H, m), 1.89 (3H, d, J = 7 Hz), 1.54 (9H, s), 1.22-1.17 (2H, m), 1.09-1.03 (2H, m).
H-NMR (400MHz, CDCl3) δppm:
8.47 (1H, d, J = 3 Hz), 8.00 (1H, d, J = 9 Hz), 7.77-7.71 (2H, m), 7.42 (1H, dd, J = 9, 3 Hz), 6.82 (1H, t, J = 9 Hz), 5.67 (1H, q, J = 7 Hz), 4.25 (2H, s), 3.46-3.39 (1H, m), 1.87 (3H, d, J= 7 Hz), 1.22-1.17 (2H, m), 1.08-1.03 (2H, m).
1H-NMR (400MHz, CDCl3) δppm:
6.95-6.84 (4H, m), 6.49-6.35 (1H, m), 5.53-5.36 (1H, m), 4.45 (1H, dd, J = 7, 4 Hz), 3.80 (3H, s), 2.06-1.90 (2H, m), 1.08 (3H, t, J= 7 Hz).
1H-NMR (500MHz, CDCl3)δppm:
7.01 (2H, d, J= 9 Hz), 6.90 (2H, d, J = 9 Hz), 4.65 (1H, t, J = 7 Hz), 3.82 (3H, s), 2.10 (2H, dq, J = 7, 7 Hz), 1.22 (3H, t, J = 7 Hz).
1H-NMR (400MHz, CDCl3)δppm:
6.95 (2H, d, J= 9 Hz), 6.83 (2H, d, J = 9 Hz), 4.70 (2H, bs), 4.38 (1H, dd, J= 7, 6 Hz), 3.77 (3H, s), 2.02-1.80 (2H, m), 1.06 (3H, t, J = 7 Hz).
1H-NMR (400MHz, CDCl3)δppm:
8.03-7.89 (3H, m), 6.97 (2H, d, J = 9 Hz), 6.81 (2H, d, J = 9 Hz), 5.25 (1H, dd, J = 7, 6 Hz), 3.76 (3H, s), 2.30-2.07 (2H, m), 1.63 (9H, s), 1.10 (3H, t, J= 7 Hz).
1H-NMR (400MHz, CDCl3)δppm:
8.02 (1H, dd, J= 8, 7 Hz), 7.95 (1H, dd, J = 8, 2 Hz), 7.89 (1H, dd, J = 11, 1 Hz), 4.92-4.86 (1H, m), 2.40-2.32 (1H, m), 2.08-1.95 (2H, m), 1.62 (9H, s), 1.05 (3H, t, J = 7 Hz).
1H-NMR (400MHz, CDCl3)δppm:
8.20-8.13 (1H, m), 8.04-7.92 (4H, m), 7.08 (2H, d, J = 8 Hz), 5.50-5.44 (1H, m), 2.85-2.55 (1H, m), 2.38-2.10 (2H, m), 1.22-1.16 (2H, m), 1.11 (3H, t, J = 7 Hz), 1.04-0.96 (2H, m).
1H-NMR (400MHz, CDCl3)δppm:
8.02 (2H, d, J =9 Hz), 6.96 (2H, d, J =9 Hz), 5.39 (1H, br s).
1H-NMR (400MHz, CDCl3)δppm:
8.02 (2H, m), 7.02 (2H, d, J = 9 Hz).
1H-NMR (400MHz, CDCl3) δppm:
7.37-7.29 (4H, m), 7.28-7.21 (1H, m), 4.05-3.98 (2H, m), 3.93-3.85 (2H, m), 3.74 (1H, d, J = 13 Hz), 2.89-2.80 (1H, m), 1.71-1.29 (10H, m), 1.10 (3H, d, J = 6 Hz).
1H-NMR (400MHz, CDCl3) δppm:
3.99 (1H, dd, J = 7, 6 Hz), 3.93 (1H, td, J = 6, 5 Hz), 3.80 (1H, dd, J = 7, 6 Hz), 3.07 (1H, qd, J = 7, 5 Hz), 1.67-1.30 (10H, m), 1.07 (3H, dd, J = 7 Hz).
1H-NMR (400MHz, CDCl3) δppm:
8.42 (1H, d, J = 2.7 Hz), 8.24-8.20 (1H, m), 8.01-7.97 (2H, m), 7.89-7.85 (1H, m), 7.83 (1H, s), 7.37-7.34 (1H, m), 6.88-6.83 (1H, m), 5.81-5.76 (1H, m), 4.26-4.21 (1H, m), 3.73-3.65 (2H, m), 3.51-3.47 (1H, m), 3.44-3.38 (1H, m), 3.23-3.19 (1H, m), 2.83-2.81 (1H, m), 1.84 (3H, d, J= 6.3 Hz), 1.42 (3H, d, J = 7.0 Hz), 1.22-1.18 (2H, m), 1.08-1.03 (2H, m);
MS (ES) m/z: 484 [M+H]+.
1H-NMR (400MHz, CDCl3) δppm:
8.23-8.19 (1H, m), 7.95 (2H, d, J= 8.6 Hz), 7.80-7.75 (2H, m), 7.67 (1H, s), 7.09 (1H, br s), 7.01 (2H, d, J = 9.0 Hz), 5.52-5.46 (2H, m), 3.81-3.78 (2H, m), 3.48-3.44 (2H, m), 2.63-2.56 (2H, m), 2.22-2.02 (2H, m), 1.19-1.16 (2H, m), 1.09-1.05 (3H, m), 0.99-0.97 (2H, m);
MS (ES) m/z: 468 [M+H]+.
1H-NMR (400MHz, CDCl3) δppm:
8.42 (1H, d, J = 2.7 Hz), 8.25-8.21 (1H, m), 7.99 (1H, d, J= 8.6 Hz), 7.82-7.76 (2H, m), 7.74 (1H, s), 7.38-7.35 (1H, m), 6.89 (1H, br s), 5.79-5.74 (1H, m), 5.28-5.24 (1H, m), 3.82-3.80 (2H, m), 3.50-3.46 (2H, m), 3.44-3.38 (1H, m), 2.35 (1H, m), 1.83 (3H, d, J = 6.7 Hz), 1.21-1.18 (2H, m), 1.08-1.03 (2H, m);
MS (ES) m/z: 455 [M+H]+.
1H-NMR (400MHz, CDCl3) δppm:
8.32-8.28 (1H, m), 8.08-8.05 (1H, m), 7.99-7.93 (3H, m), 7.09-7.05 (2H, m), 6.92-6.87 (1H, m), 5.67-5.64 (1H, m), 4.35 (1H, m), 3.85-3.80 (1H, m), 3.72-3.66 (1H, m), 2.62-2.56 (1H, m), 2.39-2.19 (3H, m), 1.33 (3H, d, J = 6.6 Hz), 1.20-1.16 (2H, m), 1.13-1.09 (3H, m), 1.01-0.96 (2H, m);
MS (FAB) m/z: 468 [M+H]+.
1H-NMR (400MHz, CDCl3) δppm:
8.16-8.12 (1H, m), 8.00-7.97 (2H, m), 7.81 (1H, s), 7.74 (1H, s), 7.72-7.71 (1H, m), 7.02-6.98 (2H, m), 6.93-6.88 (1H, m), 5.81-5.77 (1H, m), 4.35-4.31 (1H, m), 3.83-3.78 (1H, m), 3.70-3.65 (1H, m), 2.63-2.56 (2H, m), 1.83 (3H, d, J = 6.6 Hz), 1.31 (3H, d, J = 7.0 Hz), 1.21-1.18 (2H, m), 1.02-0.97 (2H, m).
MS (ES) m/z: 469 [M+H]+.
1H-NMR (400MHz, CDCl3) δppm:
8.40 (1H, d, J = 3 Hz), 8.15 (1H, t, J = 8 Hz), 8.00 (1H, d, J = 9 Hz), 7.83 (1H, s), 7.75-7.71 (2H, m), 7.32 (1H, dd, J = 9, 3 Hz), 6.93-6.85 (1H, m), 5.82 (1H, q, J= 6 Hz), 4.38-4.29 (1H, m), 3.83-3.77 (1H, m), 3.71-3.64 (1H, m), 3.45-3.37 (1H, m), 2.53 (1H, t, J = 6 Hz), 1.86 (3H, d, J = 6 Hz), 1.32 (3H, d, J = 7 Hz), 1.22-1.17 (2H, m), 1.09-1.03 (2H, m);
MS (ES) m/z: 470 [M+H]+.
1H-NMR (500MHz, CDCl3) δppm:
8.09 (2H, d, J = 8 Hz), 7.99 (2H, d, J = 8 Hz), 7.97 (2H, d, J = 9 Hz), 7.82 (1H, s), 7.02 (2H, d, J = 9 Hz), 5.49 (1H, dd, J = 7, 6 Hz), 3.28-3.22 (1H, m), 3.07 (3H, s), 2.26-2.17 (1H, m), 2.09-2.00 (1H, m), 1.43 (6H, d, J = 7 Hz), 1.09 (3H, t, J = 7 Hz).
MS (ES) m/z: 484 [M+H]+.
1H-NMR (400MHz, CDCl3) δppm:
8.43 (1H, d, J = 2 Hz), 8.19 (1H, t, J = 8 Hz), 8.01 (1H, d, J = 9 Hz), 7.92 (1H, dd, J = 8, 1 Hz), 7.80 (1H, dd, J = 12, 1 Hz), 7.68 (1H, s), 7.36 (1H, dd, J = 9, 2 Hz), 6.96-6.88 (1H, m), 5.56 (1H, q, J = 7 Hz), 4.39-4.30 (1H, m), 3.84-3.78 (1H, m), 3.71-3.65 (1H, m), 3.45-3.40 (1H, m), 2.51 (1H, t, J = 5 Hz), 1.80 (3H, d, J = 7 Hz), 1.32 (3H, d, J = 7 Hz), 1.22-1.19 (2H, m), 1.09-1.04 (2H, m).
MS (ES) m/z: 454 [M+H]+.
1H-NMR (400MHz, CDCl3)δppm:
8.42 (1H, d, J = 3 Hz), 8.21 (1H, dd, J = 8, 8 Hz), 8.01 (1H, d, J = 9 Hz), 7.91 (1H, dd, J = 8, 2 Hz), 7.78 (1H, dd, J = 13, 2 Hz), 7.67 (1H, s), 7.36 (1H, dd, J = 9, 3 Hz), 6.90-6.80 (1H, m), 5.56 (1H, q, J = 7 Hz), 3.47-3.40 (1H, m), 3.00-2.92 (1H, m), 1.79 (3H, d, J = 6 Hz), 1.23-1.18 (2H, m), 1.10-1.04 (2H, m), 0.93-0.88 (2H, m), 0.68-0.62 (2H, m).
MS (ES) m/z: 436 [M+H]+.
1H-NMR (400MHz, CDCl3)δppm:
8.42 (1H, d, J = 2 Hz), 8.27 (1H, dd J = 9, 8 Hz), 8.00 (1H, d, J = 9 Hz), 7.76 (1H, d, J = 9 Hz), 7.70 (1H, dd, J = 12, 2 Hz), 7.58 (1H, s), 7.36 (1H, dd, J = 9, 3 Hz), 7.15-7.04 (1H, m), 5.53 (1H, q, J = 6 Hz), 5.42-5.36 (1H, m), 3.85-3.76 (2H, m), 3.50-3.38 (3H, m), 2.46-2.39 (1H, m), 1.78 (3H, d, J = 7 Hz), 1.23-1.17 (2H, m), 1.09-1.02 (2H, m).
MS (FAB) m/z: 455 [M+H]+.
1H-NMR (400MHz, CDCl3) δppm:
8.47 (1H, d, J = 3 Hz), 8.21 (1H, t, J = 8 Hz), 8.03 (1H, d, J = 9 Hz), 7.98 (1H, dd, J = 8, 1 Hz), 7.85 (1H, dd, J = 12, 1 Hz), 7.39 (1H, dd, J = 9, 3 Hz), 6.97-6.85 (1H, m), 5.78 (1H, J = 7 Hz), 4.40-4.29 (1H, m), 3.81 (1H, dd, J = 11, 3 Hz), 3.68 (1H, dd, J = 11, 6 Hz), 3.47-3.37 (1H, m), 2.49 (1H, br s), 1.95 (3H, d, J = 7 Hz), 1.32 (3H, d, J = 7 Hz), 1.24-1.18 (2H, m), 1.10-1.04 (2H, m);
MS (ES) m/z: 455 [M+H]+.
1H-NMR (400MHz, DMSO-d6) δppm:
8.76 (1H, d, J = 3 Hz), 8.57 (1H, d, J = 3 Hz), 8.39 (1H, dd, J = 9, 8 Hz), 7.97 (1H, d, J = 9 Hz), 7.75-7.68 (3H, m), 6.93 (1H, t, J = 6 Hz), 6.28 (1H, q, J = 7 Hz), 4.79 (1H, t, J = 5 Hz), 3.46 (2H, q, J = 5 Hz), 3.43-3.38 (1H, m), 3.18 (2H, td, J = 6, 5 Hz), 1.84 (3H, d, J = 7 Hz), 1.09-0.98 (4H, m).
MS (ES) m/z: 456 [M+H]+.
(400MHz, CDCl3) δppm:
8.47 (1H, d, J = 3 Hz), 8.26 (1H, dd, J = 9, 8 Hz), 8.04 (1H, dd, J = 8, 1 Hz), 8.01 (1H, d, J = 9 Hz), 7.93 (1H, dd, J = 12, 1 Hz), 7.57-7.46 (1H, m), 7.43 (1H, dd, J= 9, 3 Hz), 5.74 (1H, q, J = 7 Hz), 4.28-4.22 (1H, m), 4.04-3.99 (2H, m), 3.97-3.91 (2H, m), 3.45-3.39 (1H, m), 2.46 (2H, dd, J = 7, 5 Hz), 1.91 (3H, d, J = 7 Hz), 1.22-1.17 (2H, m), 1.09-1.03 (2H, m);
MS (ES) m/z: 471 [M+H]+.
1H-NMR (400MHz, DMSO-d6) δppm:
8.92 (1H, d, J = 3 Hz), 8.52 (1H, d, J= 3 Hz), 8.48 (1H, t, J = 8 Hz), 7.94 (1H, d, J = 9 Hz), 7.91-7.85 (2H, m), 7.67 (1H, dd, J = 9, 3 Hz), 7.01 (1H, t, J = 5 Hz), 6.08 (1H, q, J = 7 Hz), 4.80 (1H, t, J = 5 Hz), 3.6 (2H, td, J = 6, 5 Hz), 3.42-3.37 (1H, m), 3.19 (2H, td, J = 6, 5 Hz), 1.77 (3H, d, J = 7 Hz), 1.07-0.98 (4H, m);
MS (ES) m/z: 456 [M+H]+.
実施例で得られた化合物5g、乳糖90g、トウモロコシデンプン34g、結晶セルロース20gおよびステアリン酸マグネシウム1gをブレンダーで混合した後、打錠機で打錠することにより、錠剤が得られる。
化合物の投与液は、0.5w/v%メチルセルロース溶液を用い、メノウ乳鉢で粉砕しながら1mg/mLの濃度になるように懸濁液を調製した。動物は、雄性C57/BL6Jマウス(日本チャールスリバー株式会社)を6週齢から8週齢で入荷し、9週齢から13週齢で使用した。試験日前日の17時から18時の間を目安に絶食を開始し、16時間から17時間程度の絶食下で試験を開始した。各群5匹ずつを用いた。尾静脈から採血を行った後、化合物懸濁液を10mg/kgとなるように経口投与した。陰性対照群には0.5w/v%メチルセルロース溶液を投与した。経口投与から25分後に尾静脈から採血を行い、経口投与から30分後に30w/v%グルコース溶液を10mL/kgで経口投与した。グルコース負荷から15分、30分、60分、120分後に尾静脈から採血を行った。採取した血液を遠心して血漿を分取し、Glucoroder-GXT(株式会社エイアンドティー)で血漿血糖値(mg/dL)を測定した。個体毎に、糖負荷5分前、糖負荷15分、30 分、60分、120分後の血糖値を用いてAUC(mg/dL・min)を算出した。群毎におけるAUC平均値を算出し、陰性対照群と比較したAUC低下率(%)を算出し、薬効の指標とした。
化合物を秤量し、溶媒(0.5w/v%メチルセルロースまたは20w/v%シクロデキストリン)中で1~10mg/mLの濃度になるように懸濁し、投与液を調製する。必要に応じ、調製した投与液を前記溶媒を用いて順次希釈し、複数の用量の投与液を調製する。動物はZucker fatty ラット(日本チャールスリバー)またはZucker diabetic fatty(ZDF) ラット(日本チャールスリバー)、雄10~18週齢を使用する。試験の2日前に血糖値、体重、血中インスリン値を測定し、各パラメータが均等になるように各群n=5から8に割り付ける。試験実施日の前日15時頃に絶食を行う。試験当日、ラットに前述の方法によって調製される化合物投与液を1~5mL/kgで経口投与し、その30分後に25~50w/v%グルコース溶液を4~5mL/kgで経口投与する。採血は化合物投与前、グルコース投与5分前、グルコース投与30、60、120および180分後に、ラット尾静脈より行う。得られた血液を遠心後、プラズマを分離し、プラズマ血糖値をGlucoroder-GXT(株式会社エイアンドティー)で測定する。各群におけるグルコース投与後の血糖値のAUCを算出し、vehicle投与群の血糖値AUCに対する低下率(%)を化合物の薬効として表記する。
Junko Ogawa, et al., Life Sciences Vol.65, No.12 pp.1287-1296 (1999) に記載の方法を参照して被検化合物のβ細胞(膵臓)保護作用を確認することができる。
Claims (15)
- 以下:
1-[4-(4-{1-[4-(シクロプロピルカルボニル)フェノキシ]プロピル}-2H-1,2,3-トリアゾール-2-イル)-2-フルオロフェニル]-3-(2-ヒドロキシエチル)ウレア;
4-{4-[(1R)-1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル]-2H-1,2,3-トリアゾール-2-イル}-N-[(1R,2R)-2,3-ジヒドロキシ-1-メチルプロピル]-2-フルオロベンズアミド;
1-(4-{4-[(1R)-1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル]-2H-1,2,3-トリアゾール-2-イル}-2-フルオロフェニル)-3-(2-ヒドロキシエチル)ウレア;
4-(5-{1-[4-(シクロプロピルカルボニル)フェノキシ]プロピル}-2H-テトラゾール-2-イル)-2-フルオロ-N-[(1R)-2-ヒドロキシ-1-メチルエチル]ベンズアミド;
4-(5-{1-[4-(シクロプロピルカルボニル)フェノキシ]エチル}-1,3-チアゾール-2-イル)-2-フルオロ-N-[(1R)-2-ヒドロキシ-1-メチルエチル]ベンズアミド;
4-[4-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,3-オキサゾール-2-イル]-2-フルオロ-N-[(1R)-2-ヒドロキシ-1-メチルエチル]ベンズアミド;
N-シクロプロピル-4-[4-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,3-オキサゾール-2-イル]-2-フルオロベンズアミド;
1-{4-[4-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,3-オキサゾール-2-イル]-2-フルオロフェニル}-3-(2-ヒドロキシエチル)ウレア;
4-{5-[(1R)-1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル]-1,2,4-オキサジアゾール-3-イル}-2-フルオロ-N-[(1R)-2-ヒドロキシ-1-メチルエチル]ベンズアミド;
1-{4-[5-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,2,4-オキサジアゾール-3-イル]-2-フルオロフェニル}-3-(2-ヒドロキシエチル)ウレア;
4-[3-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,2,4-オキサジアゾール-5-イル]-2-フルオロ-N-[2-ヒドロキシ-1-(ヒドロキシメチル)エチル]ベンズアミド;および
1-{4-[3-(1-{[6-(シクロプロピルカルボニル)ピリジン-3-イル]オキシ}エチル)-1,2,4-オキサジアゾール-5-イル]-2-フルオロフェニル}-3-(2-ヒドロキシエチル)ウレア
からなる群より選択される化合物またはその薬学的に許容され得る塩。 - 請求項1~9いずれか1項に記載の化合物またはその薬学的に許容され得る塩を有効成分として含有する医薬組成物。
- 1型糖尿病、2型糖尿病または肥満を治療するための、請求項10に記載の医薬組成物。
- β細胞または膵臓を保護するための、請求項10に記載の医薬組成物。
- 医薬組成物を製造するための、請求項1~9いずれか1項に記載の化合物またはその薬学的に許容され得る塩の使用。
- 請求項1~9いずれか1項に記載の化合物またはその薬学的に許容され得る塩を哺乳動物に投与することを含む、疾病を治療する方法。
- 哺乳動物がヒトである請求項14に記載の方法。
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES13738825.2T ES2602962T3 (es) | 2012-01-18 | 2013-01-17 | Derivado de fenilazol sustituido |
BR112014017656A BR112014017656A2 (pt) | 2012-01-18 | 2013-01-17 | composto, composição farmacêutica, e, uso de um composto |
AU2013210394A AU2013210394A1 (en) | 2012-01-18 | 2013-01-17 | Substituted phenylazole derivative |
US14/372,832 US9233958B2 (en) | 2012-01-18 | 2013-01-17 | Substituted phenylazole derivatives |
JP2013554315A JP6104181B2 (ja) | 2012-01-18 | 2013-01-17 | 置換フェニルアゾール誘導体 |
KR1020147019737A KR20140113688A (ko) | 2012-01-18 | 2013-01-17 | 치환 페닐아졸 유도체 |
CN201380014867.6A CN104159892A (zh) | 2012-01-18 | 2013-01-17 | 被取代的苯基唑衍生物 |
IN1442MUN2014 IN2014MN01442A (ja) | 2012-01-18 | 2013-01-17 | |
CA2861847A CA2861847A1 (en) | 2012-01-18 | 2013-01-17 | Substituted phenylazole derivative |
RU2014133738A RU2014133738A (ru) | 2012-01-18 | 2013-01-17 | Замещенное производное фенилазола |
SG11201404026SA SG11201404026SA (en) | 2012-01-18 | 2013-01-17 | Substituted phenylazole derivative |
NZ627303A NZ627303A (en) | 2012-01-18 | 2013-01-17 | Substituted phenylazole derivative |
EP13738825.2A EP2805941B1 (en) | 2012-01-18 | 2013-01-17 | Substituted phenylazole derivative |
MX2014008790A MX2014008790A (es) | 2012-01-18 | 2013-01-17 | Derivado de fenilazol sustituido. |
ZA2014/05108A ZA201405108B (en) | 2012-01-18 | 2014-07-11 | Substituted phenylazole derivative |
IL233682A IL233682A0 (en) | 2012-01-18 | 2014-07-17 | Modified phenylazole derivatives, preparations containing them and their uses |
PH12014501646A PH12014501646A1 (en) | 2012-01-18 | 2014-07-17 | Substituted phenylazole derivative |
HK15101292.6A HK1200824A1 (en) | 2012-01-18 | 2015-02-05 | Substituted phenylazole derivative |
US14/956,240 US9725438B2 (en) | 2012-01-18 | 2015-12-01 | Substituted phenylazole derivative |
US14/956,116 US20160081993A1 (en) | 2012-01-18 | 2015-12-01 | Substituted phenylazole derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012007840 | 2012-01-18 | ||
JP2012-007840 | 2012-01-18 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/372,832 A-371-Of-International US9233958B2 (en) | 2012-01-18 | 2013-01-17 | Substituted phenylazole derivatives |
US14/956,240 Continuation US9725438B2 (en) | 2012-01-18 | 2015-12-01 | Substituted phenylazole derivative |
US14/956,116 Continuation US20160081993A1 (en) | 2012-01-18 | 2015-12-01 | Substituted phenylazole derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013108800A1 true WO2013108800A1 (ja) | 2013-07-25 |
Family
ID=48799224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/050710 WO2013108800A1 (ja) | 2012-01-18 | 2013-01-17 | 置換フェニルアゾール誘導体 |
Country Status (21)
Country | Link |
---|---|
US (3) | US9233958B2 (ja) |
EP (2) | EP2805941B1 (ja) |
JP (2) | JP6104181B2 (ja) |
KR (1) | KR20140113688A (ja) |
CN (1) | CN104159892A (ja) |
AU (1) | AU2013210394A1 (ja) |
BR (1) | BR112014017656A2 (ja) |
CA (1) | CA2861847A1 (ja) |
CO (1) | CO7020920A2 (ja) |
ES (2) | ES2602962T3 (ja) |
HK (2) | HK1200824A1 (ja) |
IL (1) | IL233682A0 (ja) |
IN (1) | IN2014MN01442A (ja) |
MX (1) | MX2014008790A (ja) |
NZ (1) | NZ627303A (ja) |
PH (1) | PH12014501646A1 (ja) |
RU (1) | RU2014133738A (ja) |
SG (1) | SG11201404026SA (ja) |
TW (1) | TWI551590B (ja) |
WO (1) | WO2013108800A1 (ja) |
ZA (1) | ZA201405108B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015170775A1 (ja) * | 2014-05-09 | 2015-11-12 | 日産化学工業株式会社 | 置換アゾール化合物及び糖尿病治療薬 |
WO2017104782A1 (ja) * | 2015-12-17 | 2017-06-22 | 第一三共株式会社 | オキサジアゾール化合物の製造方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013108800A1 (ja) | 2012-01-18 | 2013-07-25 | 第一三共株式会社 | 置換フェニルアゾール誘導体 |
EP3766879A1 (en) * | 2019-07-19 | 2021-01-20 | Basf Se | Pesticidal pyrazole derivatives |
CN111388471B (zh) * | 2020-03-03 | 2021-01-12 | 牡丹江医学院 | 一种治疗胆囊炎的药物及其应用 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002046174A1 (en) * | 2000-12-08 | 2002-06-13 | Glaxo Group Limited | 1, 2, 4-oxadiazole derivatives as hppar alpha agonists |
WO2005061489A1 (en) | 2003-12-24 | 2005-07-07 | Prosidion Limited | Heterocyclic derivatives as gpcr receptor agonists |
WO2005115383A2 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Substituted triazoles as modulators of ppar and methods of their preparation |
WO2007003960A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
WO2007003962A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
WO2007039178A2 (en) * | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals |
WO2007116229A1 (en) | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
WO2009051119A1 (ja) | 2007-10-16 | 2009-04-23 | Daiichi Sankyo Company, Limited | ピリミジルインドリン化合物 |
WO2010115751A2 (en) | 2009-04-03 | 2010-10-14 | Merck Serono S.A. | Oxadiazole derivatives |
WO2010119881A1 (ja) | 2009-04-15 | 2010-10-21 | 第一三共株式会社 | インドリン化合物 |
WO2011016469A1 (ja) | 2009-08-05 | 2011-02-10 | 第一三共株式会社 | アミド誘導体 |
WO2011016470A1 (ja) | 2009-08-05 | 2011-02-10 | 第一三共株式会社 | スルホン誘導体 |
WO2012050151A1 (ja) | 2010-10-14 | 2012-04-19 | 第一三共株式会社 | アシルベンゼン誘導体 |
WO2013018675A1 (ja) * | 2011-07-29 | 2013-02-07 | 第一三共株式会社 | N-ヘテロ環置換アミド誘導体 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0606913D0 (en) * | 2006-04-06 | 2006-05-17 | Prosidion Ltd | Compounds |
EP2185544B1 (en) * | 2007-07-19 | 2014-11-26 | Cymabay Therapeutics, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders |
WO2013108800A1 (ja) | 2012-01-18 | 2013-07-25 | 第一三共株式会社 | 置換フェニルアゾール誘導体 |
-
2013
- 2013-01-17 WO PCT/JP2013/050710 patent/WO2013108800A1/ja active Application Filing
- 2013-01-17 EP EP13738825.2A patent/EP2805941B1/en not_active Not-in-force
- 2013-01-17 RU RU2014133738A patent/RU2014133738A/ru not_active Application Discontinuation
- 2013-01-17 EP EP15192148.3A patent/EP3009433B1/en not_active Not-in-force
- 2013-01-17 SG SG11201404026SA patent/SG11201404026SA/en unknown
- 2013-01-17 MX MX2014008790A patent/MX2014008790A/es unknown
- 2013-01-17 CA CA2861847A patent/CA2861847A1/en not_active Abandoned
- 2013-01-17 BR BR112014017656A patent/BR112014017656A2/pt not_active IP Right Cessation
- 2013-01-17 NZ NZ627303A patent/NZ627303A/en not_active IP Right Cessation
- 2013-01-17 JP JP2013554315A patent/JP6104181B2/ja not_active Expired - Fee Related
- 2013-01-17 TW TW102101765A patent/TWI551590B/zh not_active IP Right Cessation
- 2013-01-17 IN IN1442MUN2014 patent/IN2014MN01442A/en unknown
- 2013-01-17 ES ES13738825.2T patent/ES2602962T3/es active Active
- 2013-01-17 US US14/372,832 patent/US9233958B2/en not_active Expired - Fee Related
- 2013-01-17 AU AU2013210394A patent/AU2013210394A1/en not_active Abandoned
- 2013-01-17 CN CN201380014867.6A patent/CN104159892A/zh active Pending
- 2013-01-17 ES ES15192148.3T patent/ES2640667T3/es active Active
- 2013-01-17 KR KR1020147019737A patent/KR20140113688A/ko not_active Application Discontinuation
-
2014
- 2014-07-11 ZA ZA2014/05108A patent/ZA201405108B/en unknown
- 2014-07-17 PH PH12014501646A patent/PH12014501646A1/en unknown
- 2014-07-17 IL IL233682A patent/IL233682A0/en unknown
- 2014-07-31 CO CO14166876A patent/CO7020920A2/es unknown
-
2015
- 2015-02-05 HK HK15101292.6A patent/HK1200824A1/xx unknown
- 2015-02-05 HK HK16108406.3A patent/HK1220448A1/zh unknown
- 2015-12-01 US US14/956,240 patent/US9725438B2/en not_active Expired - Fee Related
- 2015-12-01 US US14/956,116 patent/US20160081993A1/en not_active Abandoned
-
2016
- 2016-12-20 JP JP2016247095A patent/JP2017052800A/ja active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002046174A1 (en) * | 2000-12-08 | 2002-06-13 | Glaxo Group Limited | 1, 2, 4-oxadiazole derivatives as hppar alpha agonists |
WO2005061489A1 (en) | 2003-12-24 | 2005-07-07 | Prosidion Limited | Heterocyclic derivatives as gpcr receptor agonists |
WO2005115383A2 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Substituted triazoles as modulators of ppar and methods of their preparation |
WO2007003960A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
WO2007003962A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
WO2007039178A2 (en) * | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals |
WO2007116229A1 (en) | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
WO2009051119A1 (ja) | 2007-10-16 | 2009-04-23 | Daiichi Sankyo Company, Limited | ピリミジルインドリン化合物 |
WO2010115751A2 (en) | 2009-04-03 | 2010-10-14 | Merck Serono S.A. | Oxadiazole derivatives |
WO2010119881A1 (ja) | 2009-04-15 | 2010-10-21 | 第一三共株式会社 | インドリン化合物 |
WO2011016469A1 (ja) | 2009-08-05 | 2011-02-10 | 第一三共株式会社 | アミド誘導体 |
WO2011016470A1 (ja) | 2009-08-05 | 2011-02-10 | 第一三共株式会社 | スルホン誘導体 |
WO2012050151A1 (ja) | 2010-10-14 | 2012-04-19 | 第一三共株式会社 | アシルベンゼン誘導体 |
WO2013018675A1 (ja) * | 2011-07-29 | 2013-02-07 | 第一三共株式会社 | N-ヘテロ環置換アミド誘導体 |
Non-Patent Citations (6)
Title |
---|
BIOORG. MED. CHEM., vol. 17, 2009, pages 7042 - 7051 |
J. MED. CHEM., vol. 52, 2009, pages 5950 - 5966 |
J. ORG. CHEM., vol. 70, 2005, pages 6346 - 6352 |
JUNKO OGAWA ET AL., LIFE SCIENCES, vol. 65, no. 12, 1999, pages 1287 - 1296 |
POVL KROGSGAARD-LARSEN ET AL.: "A Textbook of Drug Design and Development", 1996, HARWOOD ACADEMIC PUBLISHERS, pages: 351 - 385 |
See also references of EP2805941A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015170775A1 (ja) * | 2014-05-09 | 2015-11-12 | 日産化学工業株式会社 | 置換アゾール化合物及び糖尿病治療薬 |
WO2017104782A1 (ja) * | 2015-12-17 | 2017-06-22 | 第一三共株式会社 | オキサジアゾール化合物の製造方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017052800A (ja) | 置換フェニルアゾール誘導体 | |
AU2010319983B2 (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
US8975235B2 (en) | Lysophosphatidic acid receptor antagonists | |
KR20120120956A (ko) | 알킬아민 유도체 | |
KR101829086B1 (ko) | 아실벤젠 유도체 | |
JP5546542B2 (ja) | アミド誘導体 | |
US20100137387A1 (en) | Beta-keto-amide derivatives useful as ion channel modulators | |
US11426375B2 (en) | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | |
US20100137381A1 (en) | Acetamide derivatives as potassium channel modulators | |
WO2011024468A1 (ja) | 新規なスルホンアミド誘導体及びこれを含有する医薬 | |
KR20120051668A (ko) | 술폰 유도체 | |
AU2015202660A1 (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
WO2011105099A1 (ja) | 新規な4-アルコキシピリミジン構造を有する化合物及びこれを含有する医薬 | |
JP2012041309A (ja) | 新規な3−(5−エトキシピリミジン−2−イル)ピリミジン−4(3h)−オン構造を有する化合物及びこれを含有する医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13738825 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013554315 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201404146 Country of ref document: ID |
|
REEP | Request for entry into the european phase |
Ref document number: 2013738825 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013738825 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20147019737 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2861847 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 233682 Country of ref document: IL Ref document number: 14372832 Country of ref document: US Ref document number: 12014501646 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/008790 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 16116428 Country of ref document: CO Ref document number: 14166876 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2013210394 Country of ref document: AU Date of ref document: 20130117 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014133738 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014017656 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 16116433 Country of ref document: CO Ref document number: 16116442 Country of ref document: CO Ref document number: 16116444 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 112014017656 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140717 |